Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade. The LifeTime initiative is an ambitious, multidisciplinary programme that aims to improve healthcare by tracking individual human cells during disease processes and responses to treatment in order to develop and implement cell-based interceptive medicine in Europe.

中文翻译：

---

LifeTime 并通过细胞拦截医学改善欧洲医疗保健


在这里，我们描述了“LifeTime Initiative”，该计划旨在跟踪、理解和靶向复杂疾病发生和进展过程中的人类细胞，并以单细胞分辨率分析它们对治疗的反应。这一使命将通过单细胞多组学和成像、人工智能以及从健康到疾病进展过程中源自患者的实验疾病模型的开发、集成和应用来实现。对大型分子和临床数据集的分析将确定分子机制，创建疾病进展的预测计算模型，并揭示新的药物靶点和疗法。通过学术界、医院、患者协会、健康数据管理系统和行业之间的互动，将通过道德和以患者为中心的愿景及时发现和拦截疾病。该策略在单细胞水平上应用于癌症、神经和神经精神疾病以及传染性、慢性炎症和心血管疾病等关键医学挑战，将在未来十年在欧洲迎来基于细胞的拦截医学。 LifeTime 计划是一项雄心勃勃的多学科计划，旨在通过跟踪疾病过程中的单个人类细胞和对治疗的反应来改善医疗保健，以便在欧洲开发和实施基于细胞的拦截医学。